AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
-7.28%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.09B
AUM Growth
+$2.09B
(-13%)
Cap. Flow
+$264M
Cap. Flow
% of AUM
12.61%
Top 10 Holdings %
Top 10 Hldgs %
53.53%
Holding
115
New
19
Increased
31
Reduced
8
Closed
12
Top Buys
| 1 |
uniQure
QURE
|
$54.6M |
| 2 |
Black Diamond Therapeutics
BDTX
|
$42.3M |
| 3 |
Schrodinger
SDGR
|
$38.7M |
| 4 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$27M |
| 5 |
PayPal
PYPL
|
$23M |
Top Sells
| 1 |
Moderna
MRNA
|
$48.1M |
| 2 |
BioNTech
BNTX
|
$23.4M |
| 3 |
Xencor
XNCR
|
$18.9M |
| 4 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$11M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$10.2M |
Sector Composition
| 1 | Healthcare | 78.33% |
| 2 | Consumer Discretionary | 16.23% |
| 3 | Financials | 2.02% |
| 4 | Technology | 1.61% |
| 5 | Communication Services | 1.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
AC Immune
ACIU
$230M
| $6.91M | 0.29% |
1,000,000
| – | – |
|
|
HOOK
52
DELISTED
HOOKIPA Pharma
HOOK
| $6.57M | 0.28% |
796,259
-208,728
| -21% | -$1.72M |
|
|
CLVS
53
DELISTED
Clovis Oncology, Inc.
CLVS
| $6.36M | 0.27% |
1,000,000
| – | – |
|
|
AGEN
54
Agenus
AGEN
$138M
| $6.13M | 0.26% |
2,500,000
| – | – |
|
55
Merus
MRUS
$5.03B
| $6.05M | 0.26% |
500,000
| – | – |
|
56
Alector
ALEC
$272M
| $6.03M | 0.26% |
250,000
+25,000
| +11% | +$603K |
|
57
Minerva Neurosciences
NERV
$15.9M
| $6.02M | 0.25% |
1,000,000
| – | – |
|
58
Replimune Group
REPL
$457M
| $5.98M | 0.25% |
600,000
| – | – |
|
|
TBIO
59
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $5.98M | 0.25% |
600,000
-50,000
| -8% | -$499K |
|
60
Adverum Biotechnologies
ADVM
$67.1M
| $5.86M | 0.25% |
+600,000
| New | +$5.86M |
|
61
Stoke Therapeutics
STOK
$1.09B
| $5.73M | 0.24% |
+250,000
| New | +$5.73M |
|
62
Adaptive Biotechnologies
ADPT
$1.97B
| $5.56M | 0.23% |
200,000
+50,000
| +33% | +$1.39M |
|
|
AXDX
63
DELISTED
Accelerate Diagnostics
AXDX
| $5M | 0.21% |
600,000
| – | – |
|
64
Cyclerion Therapeutics
CYCN
$7.72M
| $4.93M | 0.21% |
1,861,584
+500,000
| +37% | +$1.32M |
|
65
Spero Therapeutics
SPRO
$117M
| $4.65M | 0.2% |
576,000
+76,000
| +15% | +$614K |
|
|
BLUE
66
DELISTED
bluebird bio
BLUE
| $4.6M | 0.19% |
100,000
| – | – |
|
|
IMAB
67
I-MAB
IMAB
$375M
| $4.55M | 0.19% |
+350,000
| New | +$4.55M |
|
68
Krystal Biotech
KRYS
$4.36B
| $4.32M | 0.18% |
100,000
+20,000
| +25% | +$865K |
|
69
Solid Biosciences
SLDB
$442M
| $4.3M | 0.18% |
1,800,000
| – | – |
|
|
YI
70
111 Inc
YI
$52.9M
| $4.3M | 0.18% |
650,000
| – | – |
|
|
TRIL
71
DELISTED
Trillium Therapeutics Inc.
TRIL
| $4.04M | 0.17% |
+1,000,000
| New | +$4.04M |
|
72
Kura Oncology
KURA
$719M
| $3.98M | 0.17% |
400,000
| – | – |
|
73
Passage Bio
PASG
$24M
| $3.94M | 0.17% |
+250,000
| New | +$3.94M |
|
74
Immunic
IMUX
$76.9M
| $3.81M | 0.16% |
630,019
| – | – |
|
|
APTX
75
DELISTED
Aptinyx Inc. Common Stock
APTX
| $3.6M | 0.15% |
+1,666,666
| New | +$3.6M |
|